29 results
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:49pm
and other derivatives on our shares of Common Stock and any related hedging and other trading factors.
If there is extreme market volatility and trading … ), Derivatives and Hedging (Topic 815) and Leases (Topic 842): Effective Dates, which defers the effective date of ASU 2016-13 to fiscal years beginning after
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:45pm
and other derivatives on our shares of Common Stock and any related hedging and other trading factors.
If there is extreme market volatility and trading … ), Derivatives and Hedging (Topic 815) and Leases (Topic 842): Effective Dates, which defers the effective date of ASU 2016-13 to fiscal years beginning after
10-K
2023 FY
EX-19.1
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Annual report
4:48pm
, on an exchange or in any other organized market, by directors, officers, and associates are prohibited.
Hedging Transactions. Hedging or monetization
10-K
2023 FY
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Annual report
4:48pm
derivatives on our shares of Common Stock and any related hedging and other trading factors.
If there is extreme market volatility and trading … and Hedging (Topic 815) and Leases (Topic 842): Effective Dates, which defers the effective date of ASU 2016-13 to fiscal years beginning after December 15
8-K
EX-4.1
CHRO
Chromocell Therapeutics Corp.
22 Feb 24
Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering
4:05pm
of a Warrant.
(b) This Warrant may not be sold, transferred, assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative
424B4
292o1
20 Feb 24
Prospectus supplement with pricing info
5:30pm
424B4
bnm4tx 93
20 Feb 24
Prospectus supplement with pricing info
5:28pm